enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Temsirolimus - Wikipedia

    en.wikipedia.org/wiki/Temsirolimus

    CAS Number: 162635-04-3 ... Temsirolimus, sold under the brand name Torisel, is an intravenous drug for the treatment of renal cell carcinoma (RCC), ...

  3. Sirolimus - Wikipedia

    en.wikipedia.org/wiki/Sirolimus

    CAS Number: 53123-88-9 ... these symptoms can be avoided through the use of alternate dosing regimens or analogs such as everolimus or temsirolimus. [32] Lung toxicity

  4. Sunitinib - Wikipedia

    en.wikipedia.org/wiki/Sunitinib

    CAS Number: 557795-19-4 as salt ... sorafenib (Nexavar), temsirolimus (Torisel), interleukin-2 (Proleukin), ... The number of patients in this analysis was small ...

  5. Vimseltinib - Wikipedia

    en.wikipedia.org/wiki/Vimseltinib

    This page was last edited on 23 December 2024, at 03:02 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.

  6. Osimertinib - Wikipedia

    en.wikipedia.org/wiki/Osimertinib

    Osimertinib, sold under the brand name Tagrisso, [6] is a medication used to treat non-small-cell lung carcinomas with specific mutations. [7] [8] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.

  7. Revumenib - Wikipedia

    en.wikipedia.org/wiki/Revumenib

    CAS Number: 2169919-21-3; 2169919-22-4; PubChem CID: 132212657; DrugBank: ... Clinical trial number NCT05918913 for "Expanded Access Program for Revumenib" at ...

  8. Ramucirumab - Wikipedia

    en.wikipedia.org/wiki/Ramucirumab

    Ramucirumab([5]), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer. [3] [4] Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist.

  9. Cosibelimab - Wikipedia

    en.wikipedia.org/wiki/Cosibelimab

    Cosibelimab, sold under the brand name Unloxcyt, is a monoclonal antibody used for the treatment of cutaneous squamous-cell carcinoma. [1] It is a programmed death ligand-1 (PD-L1) blocking antibody.